A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
2015 ◽
Vol 33
(4)
◽
pp. 890-894
◽
Keyword(s):
Phase 1
◽